利布雷托-431:是否是时候重新考虑对非小细胞肺癌中不常见的瘤驱动因素的随机阶段3试验了?
Alessandro Russo1, Paola Muscolino2, Christian Rolfo3
1Department of Onco-Hematology, Papardo Hospital, Messina, Italy.
Med (New York, N.Y.)
|February 10, 2024
概括
在LIBRETTO-431研究建立了一个新的第一线护理标准为RET融合阳性非小细胞肺癌 (NSCLC). 这些发现影响了先进的NSCLC治疗和用于罕见分子亚型的药物开发.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 临床试验 临床试验
背景情况:
- 非小细胞肺癌 (NSCLC) 包括各种分子亚型.
- 具有RET融合阳性的NSCLC代表了一种不常见但可向的分子变异.
- 高度NSCLC的第一线治疗策略正在不断发展.
研究的目的:
- 评估一种新型治疗方法在RET融合阳性NSCLC的第一线设置中的疗效和安全性.
- 为这种特定的NSCLC患者群体建立一个新的护理标准.
- 解决针对罕见分子亚型的向疗法所产生的临床问题.
主要方法:
- 这项研究涉及一项前性临床试验 (LIBRETTO-431).
- 参与者刚刚被诊断出RET融合阳性高级NSCLC.
- 治疗涉及特定的向治疗方案.
主要成果:
- 在LIBRETTO-431试验证明了显著的临床益处.
- 结果表明,第一线治疗的护理标准是新的.
- 该研究为不常见的NSCLC亚型的药物开发提供了关键数据.
结论:
- 来自LIBRETTO-431的发现支持RET融合阳性NSCLC的第一线治疗模式的转变.
- 这项研究对未来针对罕见分子变化的药物开发有影响.
- 优化治疗高级NSCLC需要了解不同的分子亚型.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.9K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K